Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat pharmacokinetics and safety study in pediatric sickle cell disease
2024-519881-32-00Phase 2Authorised
- Sponsor
- Novo Nordisk
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of etavopivat in sickle cell disease (SCD), sponsored by Novo Nordisk. Primary endpoints: Single-dose pharmacokinetics, Steady-state pharmacokinetics and 2 more. Planned start Oct 2026; status: authorised.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2024-519881-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519881-32-00.